Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: Applications in diagnosis and therapy

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Torres, María P ^a   Rachagani, Satyanarayana ^a   Souchek, Joshua J ^b   Mallya, Kavita ^a   Johansson, Sonny L ^a   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; MICE; MICROSCOPY, CONFOCAL; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84894332923     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080580     Document Type: Article

References (32)

1. SEER Stat Fact Sheets: Pancreas. Available: http://seer.cancer.gov/ statfacts/html/pancreas.html. Accessed 25 Jun 2013.
2. Singh M, Johnson L (2006) Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res 12: 5312-5328. (Pubitemid 44497244)
3. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450. (Pubitemid 38050041)
4. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483. (Pubitemid 40719130)
5. di Magliano MP, Logsdon CD (2013) Roles for KRAS in Pancreatic Tumor Development and Progression. Gastroenterology 144: 1220-1229.
6. Guerra C, Barbacid M (2013) Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol 7: 232-247.
7. Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909. (Pubitemid 37328891)
8. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, et al. (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44: 717-726. (Pubitemid 14184610)
9. Taylor-Papadimitriou J, Purkis P, Fentiman IS (1980) Cholera toxin and analogues of cyclic AMP stimulate the growth of cultured human mammary epithelial cells. J Cell Physiol 102: 317-321. (Pubitemid 11111639)
10. Bafna S, Singh AP, Moniaux N, Eudy JD, Meza JL, et al. (2008) MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res 68: 9231-9238.
11. Torres MP, Ponnusamy MP, Chakraborty S, Smith LM, Das S, et al. (2010) Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther 9: 1419-1431.
12. Rachagani S, Torres MP, Kumar S, Haridas D, Baine M, et al. (2012) Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. J Hematol Oncol 5: 68.
13. Moniaux N, Chaturvedi P, Varshney GC, Meza JL, Rodriguez-Sierra JF, et al. (2007) Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Br J Cancer 97: 345-357. (Pubitemid 47196741)
14. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK (2004) Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 64: 622-630. (Pubitemid 38120902)
15. Bouwens L, Braet F, Heimberg H (1995) Identification of rat pancreatic duct cells by their expression of cytokeratins 7, 19, and 20 in vivo and after isolation and culture. J Histochem Cytochem 43: 245-253.
16. Hall PA, Lemoine NR (1992) Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas. J Pathol 166: 97-103.
17. Cavallaro U, Christofori G (2004) Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann N Y Acad Sci 1014: 58-66. (Pubitemid 38594791)
18. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4: 45-60. (Pubitemid 38082153)
19. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
20. Campen CJ, Dragovich T, Baker AF (2011) Management strategies in pancreatic cancer. Am J Health Syst Pharm 68: 573-584.
21. Kurata N, Fujita H, Ohuchida K, Mizumoto K, Mahawithitwong P, et al. (2011) Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. Int J Oncol 39: 473-482.
22. Rejiba S, Bigand C, Parmentier C, Hajri A (2009) Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia 11: 637-650.
23. Greene FL, Page DL, Fleming ID, Fritz A, Balch et al. (2002) American joint committee on cancer: AJCC cancer staging manual. New York: Springer.
24. Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L (2012) Mouse models of pancreatic cancer. World J Gastroenterol 18: 1286-1294.
25. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, et al. (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57: 1731-1734. (Pubitemid 27199667)
26. Wood LD, Hruban RH (2012) Pathology and molecular genetics of pancreatic neoplasms. Cancer J 18: 492-501.
27. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353.
28. Bhadury J, Lopez MD, Muralidharan SV, Nilsson LM, Nilsson JA (2013) Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing. Oncogenesis 2: e44.
29. Wang Y, Zhang Y, Yang J, Ni X, Liu S, et al. (2012) Genomic sequencing of key genes in mouse pancreatic cancer cells. Curr Mol Med 12: 331-341.
30. Long J, Zhang Y, Yu X, Yang J, LeBrun DG, et al. (2011) Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 15: 817-828.
31. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU (2007) Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637. (Pubitemid 350160137)
32. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, et al. (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820-5828.